- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06372899
Alternative Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to communicate fluently in English (i.e. speaking, writing, and reading)
- Male and female smokers who are > 21 years of age and self-report smoking at least 5 cigarettes (menthol and/or non-menthol) per day for at least the last 6 months.
- 5 or more failed quit attempts and the use of smoking cessation medication on at least one prior attempt.
- Have a carbon monoxide (CO) greater than 10 ppm.
- Not using any forms of nicotine regularly other than cigarettes
- Be willing to switch to e-cigarettes or nicotine pouches for 6 weeks.
- Plan to live in the area for the duration of the study.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.
Exclusion Criteria:
Smoking Behavior
Regular use of nicotine-containing products other than cigarettes (e.g., chewing tobacco, snuff, snus, cigars, e-cigs, etc.). Regular e-cigarette and nicotine pouch use is defined as greater than 5 days/past 30 days.
a. Participants agreeing to abstain from using nicotine-containing products other than cigarettes for the duration of the study will be considered eligible.
- Current enrollment or plans to enroll in a smoking cessation program over the duration of the study.
- Current use of smoking cessation medication
- Provide a CO breath test reading less than 10 ppm at Intake.
Alcohol and Drug
- History of substance abuse (other than nicotine dependence) in the past 12 months.
- Current alcohol consumption that exceeds 20 standard drinks/week.
- Current use of recreational drugs (other than nicotine and cannabis)
- Breath alcohol reading (BrAC) greater than .000 at Intake.
Medical
- Women, including all individuals assigned as "female" at birth, who are pregnant, breastfeeding, or planning a pregnancy over the duration of the study period.
- Serious or unstable disease within the past year (e.g. cancer, heart disease). Applicable conditions will be evaluated on a case-by-case basis by the Principal Investigator.
Psychiatric
1. Lifetime history of schizophrenia or psychosis.
General Exclusion
- Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and/or the study design as determined by the Principal Investigator.
- Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.
- Significant non-compliance with protocol and/or study design as determined by the Principal Investigator. Subjects may be deemed ineligible at any point throughout the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ECIGS
Participants randomized to ECIGS will be provided with an e-cigarette device and be instructed to switch from smoking combustible cigarettes to using only the study-provided e-cigarette device.
Participants will be able to choose between Tobacco, Menthol, Watermelon, and Blueberry flavored nicotine pods.
They will receive their supply of nicotine pods in 7-day increments, based on baseline smoking behavior.
|
Participants randomized to ECIGS are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks.
They will be provided with an e-cigarette device and nicotine pods.
|
Experimental: ONPS
Participants randomized to ONPS will be provided with oral nicotine pouches and be instructed to switch from smoking combustible cigarettes to using only the study-provided nicotine pouches.
Participants will be able to choose between Original, Mint, Berry, and Citrus flavored nicotine pouches.
They will receive their supply of nicotine pouches in 7-day increments, based on baseline smoking behavior.
|
Participants randomized to ONPS are instructed to switch from smoking combustible cigarettes to using nicotine pouches for 6 weeks.
They will be provided with nicotine pouches.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cigarette Consumption
Time Frame: 42 days (days 8 - 49)
|
The primary outcome is the longitudinal daily count of cigarettes from baseline to the end of the switch phase.
Daily cigarette consumption will be determined by counting the daily spent cigarette filters returned for each of the 42 days (days 8 - 49).
|
42 days (days 8 - 49)
|
Cigarette Smoking Across Follow-Up
Time Frame: 19 Weeks (Day 50-6-Month Follow-Up)
|
Average cigarettes per day at the 6-month follow-up is a secondary endpoint, measured by the valid and reliable timeline follow-back (TLFB) interview.
|
19 Weeks (Day 50-6-Month Follow-Up)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarkers of Exposure: Carbon Monoxide (CO)
Time Frame: 49 days (days 1-49)
|
Carbon Monoxide (CO) will be measured using a CO monitor.
A CO > 5 ppm indicates combustible cigarette smoking.
|
49 days (days 1-49)
|
Biomarkers of Exposure: Mean mid-expiratory forced expiratory flow (FEF25% - 75%)
Time Frame: 49 days (days 1-49)
|
The mean mid-expiratory forced expiratory flow (FEF25% - 75%) is a measure of lung function and inflammation.
FEF25% - 75% will be assessed using spirometry according to the American Thoracic Guidelines.
|
49 days (days 1-49)
|
Biomarkers of Exposure: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)
Time Frame: 49 days (days 1-49)
|
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) is a primary nitrosamine marker of tobacco exposure and an often-used indicator of carcinogen exposure.
NNAL will be measured in urine and assessed through Liquid Chromatography-Tandem Mass Spectrometry per milligram creatinine (LC-MS/MS per mg creatinine).
|
49 days (days 1-49)
|
Biomarkers of Exposure:1-hydroxypyrene (1-HOP)
Time Frame: 49 days (days 1-49)
|
1-hydroxypyrene (1-HOP) is a widely used biomarker of carcinogenic polycyclic aromatic hydrocarbon exposure.
1-HOP will be measured in urine and assessed through Liquid Chromatography-Tandem Mass Spectrometry per milligram creatinine (LC-MS/MS per mg creatinine).
|
49 days (days 1-49)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 855140
- R01CA290541-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use
-
University of VirginiaVirginia Foundation for Healthy YouthRecruitingTobacco Use | Electronic Cigarette Use | Tobacco Use CessationUnited States
-
Vanderbilt University Medical CenterCompletedTobacco Use | Tobacco Use Cessation
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco DependenceUnited States
-
British American Tobacco (Investments) LimitedCompletedTobacco Use | Tobacco SmokingUnited States
-
Philip Morris Products S.A.CompletedSmoking | Tobacco Use | Tobacco SmokingUnited Kingdom
Clinical Trials on E-cigarettes
-
University of Wisconsin, MadisonNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsCompletedCardiovascular Diseases | Tobacco Use | Pulmonary Disease | E-Cigarette UseUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); University of MinnesotaRecruitingSmoking Prevention and ControlUnited States
-
Truth InitiativeVirginia Commonwealth UniversityCompletedNicotine DependenceUnited States
-
University of Southern CaliforniaNot yet recruiting
-
King's College LondonNot yet recruitingMental Health Disorder | Smoking, Tobacco | VapingUnited Kingdom
-
NYU Langone HealthCompletedSmoking | Tobacco Use DisorderUnited States
-
Cedars-Sinai Medical CenterTerminatedCoronary Artery Disease | Myocardial PerfusionUnited States
-
University of VermontNational Cancer Institute (NCI)CompletedSubstance Withdrawal SyndromeUnited States
-
University of MinnesotaNational Institute on Drug Abuse (NIDA)CompletedTobacco Use DisorderUnited States
-
University of PennsylvaniaNational Cancer Institute (NCI)Not yet recruitingSmoking | Tobacco Use | Cigarette Smoking | E-Cig Use